Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States – 2008–2012

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

Silvia de Sanjosé, Wim Quint, Laia Alemany et al. · The Lancet Oncology · 2010 · 2.7K citations

Invasive Cervical Cancer, Epidemiology, Cervical Cancer Screening +11

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014

Sarah Reagan-Steiner, David Yankey, Jenny Jeyarajah et al. · MMWR Morbidity and Mortality Weekly Report · 2015 · 834 citations · Full text

Adolescents Aged 13–17, Hpv Vaccination Coverage, Immunodeficiencies +22

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Matti Lehtinen, Jorma Paavonen, Cosette M. Wheeler et al. · The Lancet Oncology · 2011 · 693 citations

Vaccination, Cervical Cancer Screening, Hpv-16/18 As04-adjuvanted Vaccine +14

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

Darron R. Brown, Susanne K. Kjær, Kristján Sigurðsson et al. · The Journal of Infectious Diseases · 2009 · 627 citations · Full text

Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.

Shannon Stokley, Jenny Jeyarajah, David Yankey et al. · PubMed · 2014 · 537 citations · Full text

Hpv Infection, Vaccine Hesitancy, United States +24